Abstract
BackgrondWe aimed to describe 25-hydroxyvitamin D [25(OH) D] and carcinoembryonic antigen association levels in patients with locally advanced colorectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (nCRT).MethodsBetween July 2012 and September 2018, the records of 92 stage II/III colorectal cancer patients with treated with nCRT followed by radical surgery were reviewed retrospectively. Enzyme-linked immunosorbent assay (ELISA) and chemiluminescence immunoassay was used to analyze the patient’s carcinoembryonic antigen (CEA) and 25(OH) D concentrations in serum.ResultsThe serum levels of 25(OH) D in patients were significantly lower than healthy individuals, just like CEA levels were significantly higher than healthy individuals. The serum CEA in pre-nCRT was significantly lower than in post-nCRT patients, while the serum 25(OH) D from pre-nCRT patients was significantly higher than post-nCRT patients. Our results showed that the pre-nCRT CEA and 25(OH) D level is a risk factor of LARC. ConclusionsNeoadjuvant chemoradiotherapy induces a fall in circulating25(OH) D and carcinoembryonic antigen (CEA). Plasma 25 (OH) D levels is a prognostic biomarker with low 25(OH) D associated with poorer survival. Thus, serum 25(OH) D and CEA levels might be of value in evaluating the pathogenesis and risk of LARC in the future. Moreover, serum CEA or 25(OH) D levels were associated with patient's clinical and pathological features providing data for risk and prognostic prediction.
Dynamic monitoring of carcinoembryonic antigen, CA19-9 and inflammation-based indices in patients with advanced colorectal cancer undergoing chemotherapy
